PharmAla Biotech Signs Term Sheet for $100 Million U.S.
Licensing Deal for ALA-002 MDMA Therapy (MDXXF) The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing PharmAla to retain international commercialization rights
Key Investor Takeaways – PharmAla Biotech (USOTC:MDXXF) signed a term sheet to license exclusive U.S. rights to its ALA-002 MDMA therapeutic candidate to Jupiter Neurosciences (NASDAQ:JUNS). – The proposed transaction carries a potential value exceeding $100 million through upfront payments, milestone payments, and royalties. – ALA-002 is positioned as a next-generation non-racemic MDMA therapy with FDA-recognized Novel Chemical Entity status. – PharmAla would retain all ex-U.S. rights, including its Australian commercial operations through the Cortexa joint venture. – The agreement remains subject to due diligence, definitive agreements, financing, and regulatory approvals. Why MDXXF Stock Is in Focus PharmAla Biotech announced that it entered into a term sheet with Jupiter Neurosciences covering exclusive perpetual U.S. licensing rights for ALA-002, the company’s lead MDMA-based drug candidate. Under the proposed structure, PharmAla would receive upfront consideration totaling approximately $3.33 million at closing, including $1.50 million in cash and $1.83 million in Jupiter common stock.
The term sheet also outlines additional milestone payments and single-digit royalties tied to future development, regulatory approval, and commercialization milestones. Jupiter has additionally agreed to place $600,000 into escrow upon signing of the term sheet. If a definitive agreement is not completed within 90 days, PharmAla would retain the escrow amount as a reverse termination fee, subject to specified exceptions.